Leal J, Ahrabian D, Davies M J, Gray L J, Khunti K, Yates T, Gray A M
Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK.
Diabetes Research Centre, University of Leicester, Leicester, UK.
BMJ Open. 2017 Jan 9;7(1):e013592. doi: 10.1136/bmjopen-2016-013592.
Prevention of type 2 diabetes mellitus (TD2M) is a priority for healthcare systems. We estimated the cost-effectiveness compared with standard care of a structured education programme (Let's Prevent) targeting lifestyle and behaviour change to prevent progression to T2DM in people with prediabetes.
Cost-effectiveness analysis alongside randomised controlled trial.
44 general practices in Leicestershire, England.
880 participants with prediabetes randomised to receive either standard care or a 6-hour group structured education programme with follow-up sessions in a primary care setting.
Incremental cost utility from the UK National Health Service (NHS) perspective. Quality of life and resource use measured from baseline and during the 36 months follow-up using the EuroQoL EQ-5D and 15D instruments and an economic questionnaire. Outcomes measured using quality-adjusted life years (QALYs) and healthcare costs calculated in 2012-2013 prices.
After accounting for clustering and missing data, the intervention group was found to have a net gain of 0.046 (95% CI -0.0171 to 0.109) QALYs over 3 years, adjusted for baseline utility, at an additional cost of £168 (95% CI -395 to 732) per patient compared with the standard care group. The incremental cost-effectiveness ratio is £3643/QALY with an 86% probability of being cost-effective at a willingness to pay threshold of £20 000/QALY.
The education programme had higher costs and higher quality of life compared with the standard care group. The Let's Prevent programme is very likely to be cost-effective at a willingness to pay threshold of £20 000/QALY gained.
ISRCTN80605705.
预防2型糖尿病(TD2M)是医疗保健系统的首要任务。我们估计了一项针对生活方式和行为改变的结构化教育计划(“让我们预防”)与标准护理相比的成本效益,该计划旨在预防糖尿病前期患者进展为2型糖尿病。
与随机对照试验同时进行成本效益分析。
英国莱斯特郡的44家普通诊所。
880名糖尿病前期患者被随机分配接受标准护理或为期6小时的小组结构化教育计划,并在初级保健环境中进行随访。
从英国国家医疗服务体系(NHS)的角度来看的增量成本效用。使用欧洲生活质量五维度量表(EuroQoL EQ-5D)和15D工具以及一份经济问卷,在基线和36个月随访期间测量生活质量和资源使用情况。使用质量调整生命年(QALYs)衡量结局,并以2012 - 2013年价格计算医疗保健成本。
在考虑聚类和缺失数据后,发现干预组在3年内净增加0.046(95%置信区间 -0.0171至0.109)个QALYs,根据基线效用进行调整,与标准护理组相比,每位患者额外成本为168英镑(95%置信区间 -395至732)。增量成本效益比为3643英镑/QALY,在支付意愿阈值为20000英镑/QALY时,具有成本效益的概率为86%。
与标准护理组相比,教育计划成本更高,但生活质量也更高。“让我们预防”计划在获得的支付意愿阈值为20000英镑/QALY时,极有可能具有成本效益。
ISRCTN80605705。